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  This  study  aimed  to  discover  potential  biomarkers  for 
dioxynivalenol (DON) intoxication. B6C3F1 male mice were 
orally exposed to 0.83, 2.5 and 7.5 mg/kg body weight (bw) 
DON for 8 days and the differential protein expressions in 
their blood plasma were determined by SELDI - Time-of-Flight/ 
Mass  Spectrometry  (TOF/MS)  and  the  immunoglobulins 
(Igs) G, A, M and E in the serum were investigated. 11.7 kDa 
protein was significantly highly expressed according to DON 
administration and this protein was purified by employing a 
methyl ceramic HyperD F column with using optimization 
buffer for adsorption and desorption. The purified protein was 
identified as a haptoglobin precursor by peptide mapping with 
using LC/Q-TOF/MS and MALDI-TOF/MS and this was 
confirmed by western blotting and ELISA. IgG and IgM in 
serum were decreased in a dose-dependent manner and IgA 
was decreased at 7.5 mg/kg bw DON administration, but the 
IgE level was not changed. To compare the expressions of 
haptoglobin  and  the  Igs  patterns  between  aflatoxin  B1 
(AFB1), zearalenone (ZEA) and DON intoxications, rats were 
orally administered with AFB1 1.0, ZEA 240 and DON 7.5 
mg/kg bw for 8 days. Haptoglobin was increased only at 
DON 7.5 mg/kg bw, while it was slightly decreased at ZEA 
240 mg/kg bw and it was not detected at all at AFB1 1.0 mg/kg 
bw. IgG and IgA were decreased by DON, but IgG, IgA, IgM 
and  IgE  were  all  increased  by  AFB1.  No  changes  were 
observed by ZEA administration. These results show that 
plasma haptoglobin could be a diagnostic biomarker for 
DON intoxication when this is combined with examining the 
serum Igs.
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Introduction
  Deoxynivalenol (DON, vomitoxin) is a type B trichothecene 
mycotoxin that’s predominantly produced by Fusarium 
graminearum and F. culmorum during growth on crops [27, 
34]. Fusarium spp. are the most prevalent toxin-producing 
fungi in the northern regions of America, Europe and Asia 
[5]. Since DON is highly stable during the storage, processing 
and cooking of food, and even at high temperatures, human 
and animals can be exposed at high levels of DON [29]. 
Growth retardation and immune suppression are the major 
toxic effects induced by DON ingestion in farm animals 
[15,36]. High doses of DON cause feed refusal, emesis, 
skin irritation, hemorrhage and decreased weight gain [20]. 
At the cellular level, DON toxicity is induced via the 
inhibition of protein synthesis by its binding to ribosomes 
and its interference with the activity of peptidyltransferase 
[2,30]. Analyzing DON in grains or feed and the clinical 
signs such as gastroenteritis and feed refusal have been 
used for the diagnosis of DON intoxication [22]. Suppression 
of the normal immune function and superinduction of 
proinflammatory cytokines have been also suggested as 
supplementary tools for making a diagnosis, but determining 
the critical parameters for making a rapid diagnosis and 
exposure assessment are currently limited [13,27].
  A biomarker is defined as any substance, structure or 
process that can be measured in the body and it influences 
or predicts the incidence of disease [35]. For example, 
DNA adducts and some enzymes such as sulfotransferase 
A1 and epoxide hydroxylase have been validated and used as 
biomarkers for cancer detection [32]. The current advances 
in proteomics technology enable the identification of 
specific biomarkers from complex biological specimens 
[28]. Protein chip technology has been regarded as one of 
the powerful tools for the identification of potential 
biomarkers against a variety of diseases, including tumors 
and diabetes, and the protein chip platform has been 258    Eun-Joo Kim et al.
designed for more rapid profiling and identification of 
proteins [37].
  In this study, we searched for a sensitive biomarker for 
DON intoxication based on the profiles of the differential 
protein expression in blood plasma by using Surface 
Enhanced Laser Desorption/Ionization - Time of Flight/ 
Mass Spectrometry (SELDI-TOF/MS) in combination 
with the immunoglobulins (Igs) in the serum.
Materials and Methods
Animals 
  B6C3F1 male mice (8 weeks old) and Wistar male rats (7 
weeks old) were purchased from Charles River (Japan) and 
they were acclimatized to the SPF mouse and rat rooms for 1 
week. The mice and rats were fed commercial γ-irradiated 
pellets (Purina, Korea) and UV sterilized water ad libitum. 
Each animal room was maintained at 23 ± 2
oC (relative 
humidity 50 ± 10%) and a 12-h light/dark cycle. The animal 
housing and the experiment were performed according to 
the Code of Laboratory Animal Welfare Ethics, National 
Veterinary Research and Quarantine Service, Korea.
Chemicals and animal treatment
  DON, aflatoxin B1 (AFB1) and zearalenone (ZEA) were 
purchased from Sigma-Aldrich (USA) and these were 
dissolved in distilled water for DON and in corn oil for 
AFB1 and ZEA. In the experiment of mice treated with 
DON, DON was diluted to doses of 0.83, 2.5 and 7.5 mg/kg 
body weight (bw) and these doses were administered orally 
at 10 ml/kg bw via gavage once per day for 8 days to the 
mice. In the experiment of rats treated with DON, AFB1 or 
ZEA, rats were orally administered with DON 7.5, AFB1 
1.0 or ZEA 240 mg/kg bw via gavage once per day for 8 
days. The next day of the last administration, the mice or 
rats were anesthetized with diethylether and their blood 
was collected via abdominal vein and it was transferred to 
a vessel for the serum and to an EDTA-containing vessel 
for the plasma. The serum and plasma were separated by 
centrifugation at 12,000 × g for 15 min and they stored at 
-80
oC until performing the protein profiling and Igs assay. 
Protein profiling of the blood plasma protein on the 
protein chip arrays
  The blood plasma of the mice was diluted with lysis 
buffer (Urea 9.5 M, CHAPS 2% and DTT 1%) and its 
protein content was adjusted to 5 mg/ml. For the hydrophobic 
protein profiling, binding of the proteins onto the surface 
of chip (H50; Ciphergen Biosystems, USA) was conducted 
in a deep-well type assembly (Bioprocessor assembly; 
Ciphergen Biosystems, USA). The chip surface was 
activated twice by 50 μl of 50% acetonitrile for 5 min each 
time and then twice for 5 min each time by 150 μl of 
binding buffer (0.1% trifluoroacetic acid in 10% 
acetonitrile). Twenty μl of the plasma (5 mg protein/ml) 
was mixed with 80 μl of binding buffer and then this was 
applied to each spot on a H50 chip. The chip was incubated 
for 30 min with shaking at room temperature. Each spot 
was washed three times with 150 μl of binding buffer and 
once with 150 μl of distilled water for 5 min. For the 
profiling assay of the copper immobilized proteins, the 
anionic proteins, the strong or weak cationic proteins and 
the normal phased proteins, copper immobilized (IMAC30), 
anionic (Q10), cationic (CM-high and CM-low) and a 
normal phase (NP20) protein chip (Ciphergen Biosystems, 
USA) was used, respectively, and each activation and the 
binding buffer that were used for each protein chip were 
applied with following the same steps as for the 
hydrophobic protein profiling. All of the chips were 
washed after the sample reacted and they were completely 
air-dried and then treated twice with 1 μl saturated sinapinic 
acid in 50% acetonitrile and 0.5% trifluoroacetic acid. After 
complete air-drying, the chip was inserted into the Protein 
Biology Mass Specrtometry System (SELDI-TOF/MS; 
Ciphergen Biosystems, USA) for determining the mass 
peaks (time of flight) at a laser intensity of 215 and a 
detected ion sensitivity of 9. All the data was normalized 
by the total ion current and then significant mass peaks 
compared to those of vehicle control were selected by 
biomarker wizard programme (version 3.0; Ciphergen 
Biosystems, USA) and the height or area of the selected 
mass peaks was compared between each group.
Purification  and  identification  of  hydrophobic 
proteins as biomarker candidates
  The blood plasma was diluted to 5 mg protein/ml with 
adsorption buffer (1 M ammonium sulfate and 50 mM 
sodium phosphate, pH 7.0). Before the application of the 
plasma sample, a column (Methyl Ceramic HyperD F 
column; Ciphergen Biosystems, USA) was equilibrated 
twice with 200 μl of adsorption buffer. 500 μl of the diluted 
plasma sample (5 mg protein/ml) was added to the column 
and hydrophobic protein in the sample was allowed to bind 
for 30 min at room temperature. After the column was spun 
in a microcentrifuge, 500 μl of elution buffer (50 mM 
sodium phosphate pH 7.0) was applied for 10 min for four 
times each and the fraction of hydrophobic protein was 
eluted by centrifugation and the eluted fraction obtained at 
each centrifugation was combined in one vessel. 2 μl of the 
eluted fractions was applied to a gold chip to confirm that 
the targeted protein was fractionated by the mass peak 
analysis via SELDI-TOF/MS. Two ml of the eluted 
fraction was concentrated 20-fold to 100 μl with using a 
spin column that was designed for collecting materials 
with a mass range of 10,000~30,000 and then desalting 
them (VivaSpin6; VivaScience, Germany). Two μl of the 
concentrated fraction was then applied to a gold chip in 
order to reconfirm that the candidate protein with a Plasma diagnostic indicators of deoxynivalenol intoxication    259
targeted mass peak was collected by SELDI-TOF/MS 
analysis. The concentrated fraction of the protein was 
separated by 12% SDS-PAGE at 80 volts and it was 
visualized by Coomassie-blue staining [37]. The band of 
SDS-PAGE gel containing the target protein was excised and 
then the protein was digested with trypsin. The digested 
polypeptides were analyzed by LC/Q-TOF (Thermo, USA) 
and a MALDI-TOF mass spectrometer (Applied Biosystems, 
USA) and then the candidate protein was identified with 
the Mascot and ProFound protein web search engine 
(Matrix Science , USA).
Western  blotting  for  confirming  the  identified 
biomarker protein
  Twelve μl of the concentrated fraction obtained after 
column separation of the control mouse plasma or the 
DON-administered mouse plasma was mixed with 3 μl of 
sample buffer (0.5 M Tris-HCl pH6.8, 10% glycerol, 10% 
SDS, 5% 2-mercaptoethanol and 1% bromophenol blue), 
and this was heated at 95
oC for 5 min and then loaded on the 
12% SDS-PAGE. After electrophoretic running at 80 volts, 
the protein bands were transferred to a polyvinylidene 
difluoride (PVDF) membrane for 2 h at 100 volts and the 
membranes were blocked with blocking buffer (PBS 
buffer containing 0.05% Tween 20 and 7% fat free skim 
milk). The PVDF membrane was incubated for 2 h in 5 μl 
of chicken polyclonal primary antibody to haptoglobin 
diluted 1 : 1,400 along with 7 ml of blocking buffer. After 
three washes with washing buffer containing 0.05% Tween 20 
in PBS for 5 min each time, the membrane was incubated 
for 1 h in 2 μl of secondary antibody conjugated to alkaline 
phosphatase diluted 1 : 3,500 in 7 ml of blocking buffer. After 
five washes, the specific plasma protein was visualized by 
adding 5-bromo-4-chloro-3-indolyl phosphate/nitroblue 
tetrazolium as substrate for alkaline phosphatase. 
Quantitative validation by ELISA 
  The amount of haptoglobin in the blood plasma of the mice 
was quantified with using a mouse haptoglobin ELISA kit 
(Immunology Consultants, USA). The sample was diluted 
1 : 10,000 in diluent (PBS containing BSA, 0.25% Tween 
and 0.1% Proclin 300). 100 μl of the diluted sample or each 
dose standard was added to each well that was coated with 
purified anti-mouse haptoglobin and this was incubated for 15 
min at 22
oC. Following four aspirations and washings with 
washing buffer (PBS containing 0.5% Tween), 100 μl of 
diluted (1 : 100) anti-mouse haptoglobin antibodies conjugated 
with horseradish peroxidase was added to each well and 
this was incubated at room temperature for 15 min. After 
four washes, 100 μl of chromogenic substrate solution 
containing 3,3’,5,5’-tetramethylbenzidine (TMB) and 
hydroperoxide in citric acid buffer (pH 3.3) was added to 
each well. After incubation at room temperature for 10 min, 
the concentration of haptoglobin was measured at 450 nm.
Comparison of the haptoglobin expressions induced 
by DON, AFB1 and ZEA
  To confirm if haptoglobin is a specific biomarker for 
DON intoxication and exposure as compared with the 
other mycotoxins AFB1 and ZEA, the level of haptoglobin 
in the plasma of male rats (8 weeks old, Wistar; Charles 
River, Japan) that were orally administered AFB1 1.0, 
ZEA 240 or DON 7.5 mg/kg bw for 8 days was measured 
by using a mouse haptoglobin ELISA kit (Immunology 
Consultants, USA).
Determination of the immunoglobulins levels in the 
serum of the mice and rats
  The levels of immunoglobulins in the serum of the mice 
and rats were quantified with using an ELISA Quantitation 
Kit (Bethyl Lab, USA). 100 μl of goat anti-mouse or goat 
anti-rat IgG  affinity purified antibody that was diluted 1 : 
100 with coating buffer (0.05 M carbonate-bicarbonate, 
pH 9.6) was coated onto each well for 60 min at room 
temperature. Each well was washed three times with 
washing solution (50 mM Tris, 0.14 M NaCl and 0.05% 
Tween 20, pH 8.0) and the wells were blocked with 
blocking (postcoat) solution (50 mM Tris, 0.14 M NaCl 
and 1% BSA, pH 8.0) for 30 min at room temperature. The 
serum sample was diluted (1 : 1,000 for IgA and IgM and 
1 : 10,000 for IgG) in sample diluent (50 mM Tris, 0.14 M 
NaCl, 1% BSA and 0.05% Tween 20, pH 8.0). 100 μl of the 
diluted or non-diluted serum sample and each dose 
standard were then added into each well and this was 
incubated for 60 min at room temperature. After five 
aspirations and washes, 100 μl of the goat anti-mouse or 
goat anti rat Ig antibodies conjugated with horseradish 
peroxidase and diluted (1 : 50,000 for IgG, 1 : 40,000 for 
IgA, 1 : 100,000 for IgM and 1 : 20,000 for IgE) with the 
conjugate diluent (50 mM Tris, 0.14 M NaCl, 1% BSA and 
0.05% Tween 20, pH 8.0) was added to each well and this 
was incubated for 60 min at room temperature. Following 
five washings, 100 μl of the substrate solution containing 
the TMB peroxidase substrate and peroxidase solution was 
added to each well and this was incubated for 30 min at 
room temperature. To stop the TMB reaction, 100 μl of 2 M 
H2SO4 was applied to each well and the levels of the Igs 
were measured at 450 nm.
Statistical analysis
  The data is expressed as the mean ± SD of six individual 
animals. Statistical analysis was performed using ANOVA 
and then Duncan's test. A p value ＜ 0.05 was judged to be 
significant and a p value ＜ 0.01 was highly significant 
compared to vehicle control group. 260    Eun-Joo Kim et al.
Fig. 1. Protein profiles of plasma on the H50, IMAC30 and CM-low ProteinChip array surfaces. The mice were orally administered with
vehicle control (D.W.), DON 0.83, 2.5 or 7.5 mg/kg bw for 8 days, respectively. All the mass peaks were normalized by the total ion 
current (TIC) normalization function.  **p ＜ 0.01.
Results
Plasma protein profiling 
  The protein profiles of the plasma of the mice that were 
administered with DON were acquired by the protein chip 
arrays of the CM-high, CM-low, Q10, H50, IMAC30 and 
NP20 ProteinChips. The 9.7 kDa copper-immobilized 
protein and the 11.7 kDa hydrophobic protein were 
significantly increased and the 17.4 kDa weak cationic 
protein was decreased by DON in a dose-dependent manner 
(Fig. 1). Among those proteins, the 11.7 kDa hydrophobic 
protein captured on the H50 chip was the most highly 
expressed (Fig. 2). The average mean peak intensity of the 
11.7 kDa protein in the plasma of the mice that were 
administered with DON 7.5 mg/kg bw was 20 times higher 
as compared with that of the control. Plasma diagnostic indicators of deoxynivalenol intoxication    261
Fig. 3. SDS-PAGE analysis of the purified plasma 11.7 kDa 
protein. The flow-through fraction from the Methyl Ceramic 
HyperD F spin column was run on a SDS-PAGE gel and the 
proteins were stained with Coomassie blue R-250. Lane A: 
molecular marker, Lane B: Control, Lane C: DON 7.5 mg/kg bw.
Fig. 4. The 11.7 kDa protein (haptoglobin precursor) was 
reconfirmed by immunoblotting with using a polyclonal 
antibody of chicken haptoglobin. Lane A: molecular marker, 
Lane B: Control, Lane C: DON 7.5 mg/kg bw.
Fig. 2. Column optimization of the binding and elution 
conditions for the 11.7 kDa hydrophobic protein. The protein 
peaks were those of the plasma on the gold chip before loading 
onto the column (A) and those of the elutes after sample 
adsorption onto the activated column (B) and after the first and 
second desorption (C and D). 
Purification  and  identification  of  the  11.7  kDa 
hydrophobic protein
  The 11.7 kDa hydrophobic protein that was highly expressed 
in the blood plasma of mice that were administered DON 
7.5 mg/kg bw was purified by a Methyl Ceramic HyperD F 
column. The column optimizing buffer and binding buffer 
were 1 M ammonium sulfate and 50 mM sodium phosphate 
pH 7.0, respectively, and the elution buffer was 50 mM 
sodium phosphate pH 7.0. The binding and elution was 
monitored by spotting the eluates of each step on the gold chip 
and performing SELDI-TOF/MS analysis (Fig. 2). The 
11.7 kDa protein that was purified by column fractionation 
and SDS-PAGE separation (Fig. 3) was identified by 
performing LC/Q-TOF/MS and MALDI-TOF/MS along 
with using the Mascot and ProFound protein search engine 
programs. The search results showed that the top matching 
protein was haptogloin with 148 top score (p ＜ 0.05) and 
this protein showed 7% sequence coverage, as determined 
by LC/Q-TOF/MS, and the haptogloin precursor had a 
0.65 z score and 17% sequence coverage, as determined by 
MALDI-TOF/MS, respectively. 
Western blotting analysis of haptoglobin 
  To confirm the identification result of the haptoglobin 
precursor for the 11.7 kDa hydrophobic protein, western 
blotting analysis was performed using polyclonal antibody 
against chicken haptoglobin. The band of 11.7 kDa protein was 
purified by using a Methyl Ceramic HyperD F column, it 
was separated by SDS-PAGE and then the protein was 
transferred to a PVDF membrane. This was reacted with 
haptoglobin antibody and the protein was expressed at a 
higher density compared to that of the control (Fig. 4).
The  level  of  haptoglobin  in  the  blood  plasma,  as 
determined by ELISA
  In order to quantify the amount of total haptoglobin in the 
plasma, ELISA was performed with using polyclonal 262    Eun-Joo Kim et al.
Fig. 5. Changes of haptoglobin in the plasma of the B6C3F1 male
mice that were orally exposed to DON (0, 0.83, 2.5 or 7.5 mg/kg
bw, respectively) for 8 days. The data is presented as mean ± SD 
(N = 6). **p ＜ 0.01.
Fig. 6. Changes of haptoglobin in the plasma of rats orally 
exposed to DON 7.5 mg/kg, AFB1 1.0 mg/kg and ZEA 240 
mg/kg for 8 days. The data is presented as mean ± SD (N = 6). *p
＜ 0.05 . **p ＜ 0.01.  ND: not detected.
antibody against mouse haptoglobin. The blood plasma of 
the mice that were orally administered DON 0.83, 2.5 and 
7.5 mg/kg bw and vehicle control (D.W.), respectively, 
were applied to an ELISA kit. The amount of haptoglobin 
in the plasma was increased in a dose-dependent manner 
by DON (Fig. 5). That is, the normal mean value of the 
haptoglobin was 7,762.82 ng/ml, but it was increased to 
8,399.92, 12,252.95 and 22,298.18 ng/ml by DON 0.83, 
2.5 and 7.5 mg/kg bw, respectively. 
Comparison of the haptoglobin levels induced by 
DON, AFB1 and ZEA
  To confirm the potential specificity of haptoglobin as a 
biomarker for DON intoxication, we compared the 
expressions of haptoglobin in the rats with DON, AFB1 
and ZEA intoxication. The amount of haptoglobin in the 
blood plasma of the rats that were orally administered 
DON 7.5, AFB1 1.0 and ZEA 240 mg/kg bw, respectively, 
for 8 days was measured with a mouse ELISA kit. The 
normal mean value of the haptoglobin in the blood plasma 
of a rat was 209 ng/ml, and this was approximately 40 
times lower than that of the mouse. The mean value of the 
haptoglobin in the blood plasma of the rats that were 
administered DON 7.5 mg/kg bw was 1.3 times higher 
compared to that of the control, while the haptoglobin was 
completely decreased by AFB1 1.0 mg/kg bw and was 
slightly decreased by ZEA 240 mg/kg bw (Fig. 6). 
The level of the Igs in the serum of the mice
  In order to quantify the level of Igs in the serum of the 
mice, we performed ELISA using goat anti-mouse antibodies 
against IgG, IgA, IgM and IgE. The serum of the mice that 
were orally administered DON 0.83, 2.5 and 7.5 mg/kg bw, 
respectively and the vehicle control (D.W.) was applied to 
an ELISA kit. The amounts of IgG and IgM in the serum 
were decreased by DON in a dose-dependent manner and 
the IgA was decreased at 7.5 mg/kg bw DON without any 
change of the IgE (Fig. 7). 
Comparison  of  the  Igs  levels  in  the  rat  serum 
between DON, AFB1 B1 and ZEA intoxication
  To compare the expression of Igs between DON, AFB1 
and ZEA intoxication, the amounts of Igs in the serum of 
rats that were orally administered DON 7.5, AFB1 1.0 or 
zearalenone 240 mg/kg bw for 8 days were measured with 
a rat ELISA kit. IgG and IgA were decreased by DON, but 
the IgG, IgA, IgM and IgE were all increased by AFB1. No 
changes in the Igs were observed by ZEA administration 
(Fig. 8).  
Discussion
  In this study, the differentially-expressed plasma protein 
of mice exposed to DON was investigated, and the 
haptoglobin precursor in the blood plasma in combination 
with the Igs was found to be a diagnostic indicator for DON 
intoxication and exposure. 
    DON induces systemic health problems, including 
immune dysfunctions and gastroenteritis in both humans 
and animals and a reduced litter size in animals [8,9,24]. 
DON is of increasing concern for human health due to its 
prevalent contamination in cereals in the northern 
geographic regions and its sustainability during food 
processing even at high temperatures [5]. The acute oral 
toxicity (LD50) of DON in mice was determined to be 78 
mg/kg bw [6] and the minimum single oral dose that 
induced vomiting in swine was determined to be 0.075 
mg/kg bw [7]. The feed contamination level of DON in Plasma diagnostic indicators of deoxynivalenol intoxication    263
Fig. 7. Changes of the immunoglobulins content in serum by the administration of DON in B6C3F1 male mice. The values are the mean
± SD of 5 replicas. **p ＜ 0.01.
wheat and maize is reported to be less than 1 ppm. The 
level of DON that has no effect for immunologic toxicity in 
mice is between 0.25 and 0.5 mg/kg bw/day [31]. The Joint 
Expert Committee of FAO/WHO for Food Additives and 
Contaminants established a provisional maximum tolerable 
daily intake of 1 μg/kg bw, based on the no-observed-effect 
level (NOEL) of 100 μg/kg bw that doesn’t have an impact 
on the immune system, growth or reproduction [34]. 
  We selected the highest dose (7.5 mg/kg bw) of DON 
based on the LD10 in mice and we selected the lowest dose 
(0.83 mg/kg bw) that is close to the value of  NOEL (0.5 mg/ 
kg bw/day) in mice.  
  The diagnostic indicators for DON intoxication included 
a complete blood count for mild anemia and leukopenia 
and a reduced number of platelets, and the detection of DON 
in tissue or ingested feed [16,23]. However, diagnostic 
confirmation by DON detection is difficult because DON 
is rapidly metabolized and excreted as a de-epoxidation 
metabolite or as a conjugated DON form into the bile and 
urine [22]. The development of useful diagnostic 
parameters is needed for the rapid detection of DON 
intoxication. 
  The SELDI-TOF/MS technique has provided a proteomic 
high throughput approach that can discover potential 
biomarkers along with determining their mass and charge 
[37]. Many candidate biomarkers have been found by the 
SELDI-TOF/MS technique such as amyloid-β peptide for 
Alzheimer’s disease [14,28], α-defensin 1, 2 and 3 for 
immunodeficiency and so on [38].
  In the present study, we profiled the plasma proteins that were 
sensitive to reaction with DON by using SELDI-TOF/MS 
technology, and we identified the haptoglobin precursor as 
a useful protein biomarker for DON intoxication. 
  Haptoglobin is a glycoprotein that’s mainly synthesized and 
secreted by liver cells [3,17]. Cancer cells and interstitial 
seminiferous and endometriotic epithelium were also recently 
reported to produce haptoglobin [25]. Haptoglobin consists 
of α1 and α2 subunits and these may link to glycosylated 
β-subunits via disulfide bonds [37]. Haptoglobin functions as 
a hemoglobin (Hb) scavenger by binding to free Hb released 
from erythrocytes and thereby inhibits Hb’s oxidative 
activity and allows heme iron recycling. Haptoglobin is 
increased in patients with acute inflammatory disease as 
one of positive acute phase proteins (APPs) and it is involved 264    Eun-Joo Kim et al.
Fig. 8. Changes of the immunoglobulin content in the serum of Wistar male rats by the administration of DON, AFB1 and ZEA. The
rats were administered with DON (7.5 mg/kg), AFB1 (1.0 mg/kg) or ZEA (240 mg/kg) by gavage once per day for 8 days. The values
are the mean ± SD of 5 replicas. *p ＜ 0.05, **p ＜ 0.01.
in the regulation of epidermal cell transformation, immune 
suppression and angiogenesis [21,37]. Ye et al. [37] 
reported that the haptoglobin-α subunit (MW 11,700 Da) is 
a potential serum biomarker in human ovarian cancer and 
it is related with immunosuppression in cancer patients. 
The release of APPs from hepatocytes and other APPs 
producing organs was stimulated by pro-inflammatory 
cytokines such as IL-6, IL-1 and TNF-α, as well as by 
malnutrition [1,11,19]. DON was observed to upregulate 
pro-inflammatory cytokines production in vitro and in 
mice [24,27]. Though the direct reason for the increased 
haptoglobin by DON was not investigated in the present 
study, the increased haptoglobin may be related to immune 
dysfunction, malnutrition and gastroenteritis, which are all 
induced by DON. 
  In our former study [12], feed consumption, body weight 
gain and the absolute and relative weight of the thymus 
were decreased and mucosal ulceration and submucosal 
edema of the stomach were found according to oral DON 
administration of 0.83, 2.5 or 7.5 mg/kg bw in mice. DON 
was also reported to cause a significant reduction of the 
thymic and splenic weights and depress the stimulation of 
B and T cells by mitogenes [26]. IgG, IgA and IgM 
secretion was significantly impaired in cultured murine 
lymphocytes that were exposed to DON [33]. Our study 
also showed decreased IgG, IgA and IgM in B6C3F1 mice 
with oral DON administration in a dose dependent manner.
  Grange  et al. [10] showed that there was an inverse 
relationship between haptoglobin levels and the circulating 
lymphocyte count in tuberculosis patients. In this study, the 
levels of haptoglobin and IgG, IgA and IgM showed a 
reciprocal relationship according to DON administration. 
IL-1, IL-6 and TNF-α are the main proinflammatory 
cytokines that stimulate the release of APPs, which were 
reported to be formed during the acute phase response 
associated with anorexia [11]. Low protein synthesis and 
anorexia are the main symptoms of DON intoxication. 
  In our study, haptoglobin was increased only by DON, but 
not by ABF1 and ZEA. Haptoglobin was slightly decreased 
by 240 mg/kg bw ZEA and it was completely decreased to 
the undetectible range by 1 mg/kg bw AFB1 in rats. 
However, IgG and IgA were suppressed by DON 7.5 Plasma diagnostic indicators of deoxynivalenol intoxication    265
mg/kg bw, but all the Igs (IgG, A, M and E) were increased 
by AFB1 1 mg/kg bw, and no changes in the Igs were 
observed by ZEA 240 mg/kg bw. AFB1 is a typical 
hepatotoxicant that induces centrilobular hemorrhagic 
hepatic necrosis and cancer [23]. AFB1 inhibits protein 
synthesis by modifying the DNA template and depressing 
the synthesis of messenger RNA, which may explain the 
reduction of haptoglobin synthesis in the liver by AFB1. 
ZEA binds to cytosolic estradiol-17β receptors and 
functions as a weak estrogen [23]. Estrogen-deficient rats 
showed an increased production of pro-inflammatory 
cytokines, which was attenuated by estrogen-replacement 
[4]. The slight reduction of haptoglobin by ZEA may be 
understood according to the inverse relationship between 
estrogen and proinflammatory cytokines. Our present study 
suggests that haptoglobin induction and Igs suppression 
can be used to discriminate between DON intoxication 
from ZEA and AFB1 intoxication when a case of 
mycotoxicosis is suspected.
  Haptoglobin is a positive APP, and it is increased in the 
blood plasma by bacterial infectious diseases and viral 
diseases, and for this reason haptoglobin has been suggested 
to be a landmark for disease control. Chronic bacterial 
infections are usually accompanied with induction of Igs, 
and especially IgG [18]. But in the case of DON intoxication, 
an increase of haptoglobin with a decrease of IgG, IgA or 
IgM was observed, and this can help differentiate DON 
intoxication from infectious disease. 
  In conclusion, haptoglobin can be used as a biomarker for 
DON intoxication and exposure, and especially when the 
Igs are combined into an index.
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